Germ Cell Tumors Clinical Trials

A listing of Germ Cell Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 1021 clinical trials
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

esophageal cancer
gastric cancer
cell transplantation
myeloid leukemia
cancer of the ovary
  • 03 May, 2022
  • 7 locations
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every …

peritoneal cancer
monoclonal antibodies
fallopian tube
breast cancer
  • 30 Jun, 2022
  • 13 locations
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. …

large b-cell lymphoma
peripheral t-cell lymphoma
  • 03 Jul, 2022
  • 30 locations
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors for Immunotherapy of Advanced Solid Tumors

This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab and to compare their differences.

total bilirubin
measurable disease
solid tumors
  • 01 Feb, 2022
  • 1 location
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Topotecan, and Pegylated liposomal doxorubicin (PLD) …

  • 24 Apr, 2022
  • 13 locations
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health …

precision medicine
solid tumor
  • 15 Jun, 2022
  • 1 location
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular …

Accepts healthy volunteers
residual disease
cancer diagnosis
precision medicine
clinical decision-making
  • 24 Apr, 2022
  • 1 location
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (GLIMMER-01)

This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with pembrolizumab.

renal function
pancreatic cancers
breast cancer
cancer of the ovary
  • 14 Jun, 2022
  • 5 locations
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.

formalin-fixed paraffin-embedded
solid tumor
  • 09 Aug, 2022
  • 63 locations
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 [PD-1] antibody), in patients …

programmed cell death 1 ligand 1
combination therapy
monoclonal antibodies
growth factor
measurable disease
  • 25 Mar, 2022
  • 3 locations